Top Companies in Retinal Disorder Treatment Market
The Global Retinal Disorder Treatment Market is expected to grow with ~8.10% CAGR during the forecast period 2019-2026. As per the analyst, the market valued ~$8.73 billion in the year 2018.
The Retinal Disorder Treatment Market growth is supported by various driving factors, among which increasing cases of retinal disorder is majorly influencing the market growth. Increasing awareness related to availability of treatment methods, increasing prevalence of diabetes, increasing geriatric population and collaborative initiatives taken by market players are some supportive factors impacting the market growth positively. Also, technical advancements in the field of retinal disorder treatment methods and equipment is further boosting the market growth.
Acucela Inc. (Kubota Pharmaceutical Holdings Co., Ltd.), Novartis AG, Graybug Vision, Inc., Bayer AG, Shire (Takeda Pharmaceutical Company Limited), Allergan plc, Pfizer, Inc., F. Hoffmann-La Roche Ltd., Regeneron Pharmaceuticals, Inc. and Santen Pharmaceutical Co., Ltd. are some major players profiled in the research study. Companies are adopting various competitive strategies to withhold the maximum market share and gain a competitive edge in the market for the long-term.
Santen Pharmaceutical Co., Ltd.
Santen Pharmaceutical Co., Ltd. was founded in the year 1890 and the company is based in Japan. The company deals in ophthalmic medicine and manufactures a wide range of products including eye ointments and eye drops. The company also imports lenses and equipment and tools used by optometrists. The company is involved in research and development, sales and marketing of medical devices and over-the-counter products.
February 2020, Joint Venture: Santen Pharma announced the joint venture with Verily. This joint venture will include artificial intelligence machine learning, integrated and connected medical devices with ophthalmology practices to commercialize and develop unique Ophthalmic Devices. Verily’s advanced digital technology and Santen’s commercial and industrial ophthalmology business platform will be used to pursue innovations in the field of ophthalmology field.
January 2020, Partnership: Santen Pharmaceutical entered into a partnership with the International Telecommunication Union (ITU) to support the collaborative initiative of the ITU and the WHO titled ‘Be healthy, Be Mobile’. The initiative is focused upon prevention of non-communicable disease in the ophthalmology field.
January 2020, Expansion: Santen announced the construction of company’s second plant in China to meet the rising demand for company’s products in China. The company gain majority of its sales from China and Asia region i.e. approx. 60% of the total sales. Improvements in healthcare system of China and high economic growth increase the spending capacity of patients in turn boosting the ophthalmology market in the region.
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. was founded in the year 1988 and the company is based in the United States. It is a biopharmaceutical company that is involved in commercialization, development and discovery of pharmaceutical products used in the treatment of serious medical conditions.
May 2019, FDA Approval: Regeneron Pharmaceuticals announced the FDA approval of YLEA® (aflibercept) Injection that can treat all stages of diabetic retinopathy (DR).
F. Hoffmann-La Roche Ltd.
F. Hoffmann-La Roche Ltd. was founded in the year 1896 and the company is based in Switzerland. The company provides drugs and in-vitro diagnostics for transplantation and cancer treatment. The Company specializes in medicines for microbiology, infectious diseases, genetics, blood screening, urinalysis, immunology, clinical chemistry, CNS, metabolism, inflammation, virology and oncology. The company is involved in research and development in the Ophthalmology segment.
Get detailed insights related to company profiles included in the research report by Report Ocean, visit us at https://www.reportocean.com/industry-verticals/details?report_id=bw324